Back to discover

Protein / target

PR domain zinc finger protein 1

Encoded byPRDM1O75626Homo sapiensSwiss-Prot
UniProt: O75626Ensembl: ENSG00000057657HGNC: HGNC:9346NCBI Gene: 639
Degrader-tractable
Druggability
UniProt Ubiquitination
1
Research papers

Protein at a glance

Biological role

Sequence-specific double-stranded DNA binding

Strongest disease association

Inflammatory Bowel Diseases

Via encoding gene PRDM1 · Genetic evidence · score 0.76

Research activity

Emerging research

1 papers · latest 2015

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Transcription factor that mediates a transcriptional program in various innate and adaptive immune tissue-resident lymphocyte T cell types such as tissue-resident memory T (Trm), natural killer (trNK) and natural killer T (NKT) cells and negatively regulates gene expression of proteins that promote…

View complete UniProt function annotation

Transcription factor that mediates a transcriptional program in various innate and adaptive immune tissue-resident lymphocyte T cell types such as tissue-resident memory T (Trm), natural killer (trNK) and natural killer T (NKT) cells and negatively regulates gene expression of proteins that promote the egress of tissue-resident T-cell populations from non-lymphoid organs. Plays a role in the development, retention and long-term establishment of adaptive and innate tissue-resident lymphocyte T cell types in non-lymphoid organs, such as the skin and gut, but also in other nonbarrier tissues like liver and kidney, and therefore may provide immediate immunological protection against reactivating infections or viral reinfection (By similarity). Binds specifically to the PRDI element in the promoter of the beta-interferon gene (PubMed:1851123). Drives the maturation of B-lymphocytes into Ig secreting cells (PubMed:12626569). Associates with the transcriptional repressor ZNF683 to chromatin at gene promoter regions (By similarity). Binds to the promoter and acts as a transcriptional repressor of IRF8, thereby promotes transcription of osteoclast differentiation factors such as NFATC1 and EEIG1 (By similarity)

Subcellular location

NucleusCytoplasm
Domains and Gene Ontology detail (23)

Domains & features

SET

Gene Ontology

  • Ccytoplasm
  • Cnucleolus
  • Cnucleoplasm
  • Cnucleus
  • FDNA-binding transcription factor activity
  • FDNA-binding transcription repressor activity, RNA polymerase II-specific
  • Fhistone methyltransferase binding
  • Fmethyltransferase activity
  • Fpromoter-specific chromatin binding
  • FRNA polymerase II cis-regulatory region sequence-specific DNA binding
  • Fsequence-specific double-stranded DNA binding
  • Fzinc ion binding

825 aa · 92 kDa · 3 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Immune signallingUniProt · GOTranscriptional regulationUniProt · GO
View supporting evidence

Immune signalling

  • ·Transcription factor that mediates a transcriptional program in various innate and adapt…
  • ·adaptive immune response
  • ·innate immune response
  • ·regulation of extrathymic T cell differentiation

Transcriptional regulation

  • ·Transcription factor that mediates a transcriptional program in various innate and adapt…
  • ·DNA-binding transcription factor activity
  • ·DNA-binding transcription repressor activity, RNA polymerase II-specific
  • ·RNA polymerase II cis-regulatory region sequence-specific DNA binding

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene PRDM1

Gene-level evidence surfaced through the gene PRDM1that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Colitis, Ulcerative
0.77Well supported

Genetic evidence dominant · Open Targets 0.48

Inflammatory Bowel Diseases
0.77Well supported

Genetic evidence dominant · Open Targets 0.47

Alopecia
0.70Moderately supported

Genetic evidence dominant · Open Targets 0.43

Crohn's Disease
0.69Moderately supported

Genetic evidence dominant · Open Targets 0.42

Psoriasis
0.67Moderately supported

Genetic evidence dominant · Open Targets 0.41

View evidence synthesis (5)
Colitis, UlcerativeWell supported
0.77
agreement 0.66–0.87
Genetic75%Somatic mutation21%RNA expression3%Literature1%

Open Targets aggregate 0.48 · 4 independent evidence families

Inflammatory Bowel DiseasesWell supported
0.77
agreement 0.64–0.89
Genetic95%Literature5%RNA expression1%

Open Targets aggregate 0.47 · 3 independent evidence families

AlopeciaModerately supported
0.70
agreement 0.58–0.82
Genetic100%

Open Targets aggregate 0.43 · 1 independent evidence family

Crohn's DiseaseModerately supported
0.69
agreement 0.57–0.82
Genetic96%RNA expression2%Literature2%

Open Targets aggregate 0.42 · 3 independent evidence families

PsoriasisModerately supported
0.67
agreement 0.55–0.80
Genetic92%RNA expression5%Literature4%

Open Targets aggregate 0.41 · 3 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Colitis, Ulcerative0.48
Inflammatory Bowel Diseases0.47
Lymphoma, Large B-Cell, Diffuse0.44
Alopecia0.43
Neurodegenerative Diseases0.42
Crohn's Disease0.42
Psoriasis0.41
Melanoma0.38
Primary central nervous system lymphoma0.37

Tractability

Protein degraders — Emerging

Feasibility evidence (uniprot ubiquitination and database ubiquitination) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (2)
PR · UniProt UbiquitinationPR · Database Ubiquitination

Raw Open Targets tractability assessment buckets, by modality.

Research activity

1 papers · to 2015

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

T-cell exhaustion in the tumor microenvironment.852 cites

Jiang Y · Cell death & disease · 2015

Recent

T-cell exhaustion in the tumor microenvironment.

Jiang Y · Cell death & disease · 2015

Europe PMC papers linked directly to this protein.